25-Nov-2025 6:30 AM CST - Business Wire Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 am ET in Miami, Florida. A live webcast of the fireside chat can be accessed under Events & Presentations on the Companys website at www.vera
4-Nov-2025 6:30 AM CST - Business Wire Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the third quarter ended September 30, 2025. "Our performance in Q3, which was the first full quarter since our accelerated approval and launch of AVMAPKI FAKZYNJA CO-PACK, exceeded expectations with net revenue of over $11 million and demonstrated the stre
23-Oct-2025 6:30 AM CST - Business Wire Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 8194537 at
27-Aug-2025 6:00 AM CST - Business Wire Verastem Oncology to Present at Upcoming Investor Conferences Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3 at 3:55 pm ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Monday, September 8
7-Aug-2025 3:05 PM CST - Business Wire Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the second quarter ended June 30, 2025. In the second quarter of 2025, AVMAPKI FAKZYNJA CO-PACK became the first-ever treatment approved by the FDA specifically for use in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, and we are of
29-Jul-2025 6:30 AM CST - Business Wire Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at
2-Jun-2025 8:40 AM CST - Business Wire Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall
28-May-2025 6:30 AM CST - Business Wire Verastem Oncology to Present at the Jefferies Global Healthcare Conference Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York. A live webcast of the fireside chat can be accessed under Events & Presentations on the Companys website at www.verastem.com. A
25-Nov-2025 6:30 AM CST - Business Wire Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 am ET in Miami, Florida. A live webcast of the fireside chat can be accessed under Events & Presentations on the Companys website at www.vera
4-Nov-2025 6:30 AM CST - Business Wire Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the third quarter ended September 30, 2025. "Our performance in Q3, which was the first full quarter since our accelerated approval and launch of AVMAPKI FAKZYNJA CO-PACK, exceeded expectations with net revenue of over $11 million and demonstrated the stre
23-Oct-2025 6:30 AM CST - Business Wire Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 8194537 at
27-Aug-2025 6:00 AM CST - Business Wire Verastem Oncology to Present at Upcoming Investor Conferences Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3 at 3:55 pm ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Monday, September 8
7-Aug-2025 3:05 PM CST - Business Wire Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the second quarter ended June 30, 2025. In the second quarter of 2025, AVMAPKI FAKZYNJA CO-PACK became the first-ever treatment approved by the FDA specifically for use in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, and we are of
29-Jul-2025 6:30 AM CST - Business Wire Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at
2-Jun-2025 8:40 AM CST - Business Wire Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall
28-May-2025 6:30 AM CST - Business Wire Verastem Oncology to Present at the Jefferies Global Healthcare Conference Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York. A live webcast of the fireside chat can be accessed under Events & Presentations on the Companys website at www.verastem.com. A
